Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. Show More...

  • Website https://www.pumabiotechnology.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 3.28 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.51 -3.42 -1.9 -4.73 -7.45 -8.29 -7.85 -2.99 -1.95 -2.12
    Dividends USD
    Payout Ratio % *
    Shares Mil 8.0 20.0 22.0 29.0 30.0 32.0 33.0 37.0 38.0 39.0 39.0
    Book Value Per Share * USD 4.5 3.27 4.64 7.54 2.48 2.11 1.19 0.44 0.24
    Free Cash Flow Per Share * USD -2.07 -2.38 -2.47 -4.49 -4.33 -4.87 -3.11 0.72
    Return on Assets % -36.94 -71.8 -42.69 -106.29 -118.87 -112.06 -139.59 -53.49 -30.6 -29.61
    Financial Leverage (Average) 1.0 1.02 1.18 1.24 1.39 1.16 1.2 3.11 7.55 13.45 24.05
    Return on Equity % -37.64 -81.13 -51.35 -141.23 -148.14 -132.75 -221.91 -259.28 -292.05 -311.99
    Return on Invested Capital % -37.65 -81.24 -51.51 -141.56 -148.74 -133.21 -162.46 -72.5 -38.85 -40.32
    Interest Coverage -404.49 -9.34 -4.03 -5.04
    Current Ratio 91.54 6.86 5.0 3.36 6.89 6.31 1.82 3.02 1.83 1.75
    Quick Ratio 91.06 6.82 4.87 3.22 6.65 6.13 1.57 2.79 1.55 1.46
    Debt/Equity 0.91 4.43 6.73 12.55